Symbols

OMGA(Delisted)

Omega Therapeutics·NASDAQ

--(--)

Signals Analysis

Bullish signal 1

Bearish signal 0

EPS Beats Expectation

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About OMGA

Omega Therapeutics, Inc.

A clinical-stage biotechnology company that pioneering the first systematic approach to use mRNA therapeutics as a new class of programmable epigenetic medicines

Industry

Established Date

Listing Date

07/30/2021

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

ir.omegatherapeutics.com

Security Type

Common stock

Office address

140 First Street, Suite 501, Cambridge, Massachusetts 02141

Business

Introduction

Omega Therapeutics, Inc., was incorporated as a Delaware corporation in July 2016. The company is a clinical-stage biotechnology company that has pioneered a new class of programmable epigenomic mRNA drugs. The company's OMEGA platform utilizes the power of epigenetics and a deep understanding of genomic structure to precisely target and controllably regulate gene expression at the pre-transcriptional level to treat or cure diseases.

Company Financials

EPS

OMGA has released its 2024 Q3 earnings. EPS was reported at -0.3, versus the expected -0.27, missing expectations. The chart below visualizes how OMGA has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

OMGA has released its 2024 Q3 earnings report, with revenue of 2.61M, reflecting a YoY change of 214.32%, and net profit of -16.44M, showing a YoY change of 26.09%. The Sankey diagram below clearly presents OMGA's revenue sources and cost distribution.